Vygon

	Contact
	Téléphone : +33 (0)1 39 92 63 63 Mail : Adresse : 5 rue Adeline 95440 Ecouen France Web : www.vygon.fr

	Consultez cette fiche en intégralité ?
	Consultez cette fiche et près de 50 000 autres fiches de Centres de Recherche dans plus de 30 pays européens sur Expernova.com ! Inscrivez-vous ou contactez-nous pour une démonstration personnalisée. Il s’agit de votre centre de Recherche ? Inscrivez-vous gratuitement et complétez vos informations.

	Description (Extrait du site web)
	Vygon is a company that creates, produces and markets single-use sterile medical and surgical products. Recently, Vygon has developed its activities in responding to each individual client, by offering ready-to-use packs and sets. This strategy helps to reduce workload and optimizes safety at a competitive rate. The Vygon Company strategy is clear, offer health professionals efficient and innovative single-use medical products adapted to their needs. With a high degree of quality and at a competitive price, we offer health-care professionals the best possible chances to treat and care for their patients in the most secured conditions. Innovation requires an understanding: our teams of marketing, R&D and sales representatives are working daily with our customers, listening to their needs, bringing creative and imaginative solutions to patient care. This high quality and responsive service compliments the proximity of production and research. That is why our plants are still located in Europe and in the United States of America. It?s our key to ensure constant high quality products. This policy and strategy, requires long term commitment and a real involvement of all Vygon partners and managers. Stability and commitment of our shareholders enable us to invest in the long term, opting for quality and innovation instead of short term profitability, giving our teams and clients the warranty of a long term vision that everybody needs. This willingness to act in the long term, some talk about Sustainable Development Strategy (SDS), allows Vygon to implement its leading vision of progress, integrating all stakeholders, in social, economic and environmental outcomes. This strategy has proven to be effective. Since fifty years now, Vygon attracts more and more partners around the world. We are now present in more than one hundred countries in five continents. Our regular growth and profitability, warranty of our independence and our ability to innovate, testifies the quality of our products and our customer satisfaction.

	Profil scientifique partiel

	Quelques documents de Vygon
	Development of biomaterials with improved resistance to infection 1997 - 2000 Sujets : Safety, Materials Technology, Industrial Manufacture Type de contrat : Cost-sharing contracts Participants : ROYAL INSTITUTE OF TECHNOLOGY SVERIGE ROYAL INSTITUTE OF TECHNOLOGY Education,Other DEPARTMENT OF POLYMER TECHNOLOGY@@@ Teknikringen 56-58 100 44 SVERIGE University of Patras HELLAS University of Patras Education Biomedical Engineering Laboratory Riow 26110 HELLAS UNIVERSITÀ DEGLI STUDI DI SIENA ITALIA UNIVERSITÀ DEGLI STUDI DI SIENA Education INTERUNIVERSITY RESEARCH CENTER FOR ADANCED MEDICAL SYSTEMS Via Ettore Bastianini 12 53100 ITALIA WAGENINGEN UNIVERSITY NEDERLAND WAGENINGEN UNIVERSITY Education,Other PHYSICAL AND COLLOID CHEMISTRY 6,Dreijenlaan 6 Scheikundegebouw 6703 HB NEDERLAND Ergo S.A. HELLAS Ergo S.A. Other 15,AG Orous Street 15123 HELLAS Humboldt-Universität zu Berlin DEUTSCHLAND Humboldt-Universität zu Berlin Education Virchow-Klinikum Experimentelle Chirurgie - Abteilung für Chirurgie und Transplantationsmedizin 1,Augustenburger Platz 13353 DEUTSCHLAND UNIVERSITE CLAUDE BERNARD LYON 1 FRANCE UNIVERSITE CLAUDE BERNARD LYON 1 Education UMR 5586 - DEPARTEMENT DE PHYSIQUE DES MATERIAUX 43,Boulevard du 11 Novembre 1918, 43 69622 FRANCE VYGON SA FRANCE VYGON SA Other TECHNICAL DEPARTMENT 5-11,Rue Adeline 5-11 95440 FRANCE Enterprise Ireland - Trading as Bioresearch Ireland ÉIRE/IRELAND Enterprise Ireland - Trading as Bioresearch Ireland Research Ceramics Research Centre Glasnevin ÉIRE/IRELAND BIOMATECH France BIOMATECH Industry Rue Pasteur 115, Z.I. L'Islon 38670 France BELLCO Italy BELLCO Industry CLINICAL AND LABORATORY RESEARCH DEPARTMENT Via Camurana 1A Italy Hide general information Medical Devices represent half of the nosocomial complications in the hospital (25 40 % of intravenous catheters are infected after 5 7 days). They are related to a relative affinity of bacteria to adhere on an artificial surface, and to develop a biofilm structure which isolate microorganisms from conventional therapies. End users and Industrials are highly concerned by morbidity and health care costs of infection. Although antibiotic bounding and silver treatment of the materials have already been proposed, their efficacy, safety and long term performances have not been established. This fundamental research program is dealing with the screening of more than 10 different surface treatment for polymers in order to design an "anti bacterial" interface. These techniques of potential interest in developping antibacterial surfaces will include: Design of specific antibacterial activity (silver, quaternary ammonium, carbon like coating + Ag, silver iodide, antiseptics). Grafting of biological molecules within the bulk or on the surface (heparin is of high potential interest). Development of non fouling surfaces concept (PEO like, PEO repelling, teflon like, suprahydrophilic, microstructurated) The activity of these materials will be screened on bacterial strains and in conditions representative of the clinical use. A fundamental approach of biofilm expression and regulation according to the different polymeric surfaces and treatments is included as an important step for the understanding of the effects. The project will be in a second time (after month 20) restricted to efficient surface treatments and to those for which the risk benefit ratio is acceptable.Polymeric changes induced by the treatment, optimization of sterilization conditions will be investigated. 5 academic partners who developped and fully control these technologies and 5 industrial partners, including 2 CRO's, will participate to this extensive project. Due to its important impact, the project is exceeding 30 % of the total cost allowed for basic research projects. However, this size expresses also the need for an EU level programme since no single partner would be able to develop it individualy. Source : cordis   Development of biomaterials with improved resistance to infection 1997 - 2000 Sujets : Safety, Materials Technology, Industrial Manufacture Type de contrat : Cost-sharing contracts Participants : ROYAL INSTITUTE OF TECHNOLOGY SVERIGE ROYAL INSTITUTE OF TECHNOLOGY Education,Other DEPARTMENT OF POLYMER TECHNOLOGY@@@ Teknikringen 56-58 100 44 SVERIGE University of Patras HELLAS University of Patras Education Biomedical Engineering Laboratory Riow 26110 HELLAS UNIVERSITÀ DEGLI STUDI DI SIENA ITALIA UNIVERSITÀ DEGLI STUDI DI SIENA Education INTERUNIVERSITY RESEARCH CENTER FOR ADANCED MEDICAL SYSTEMS Via Ettore Bastianini 12 53100 ITALIA WAGENINGEN UNIVERSITY NEDERLAND WAGENINGEN UNIVERSITY Education,Other PHYSICAL AND COLLOID CHEMISTRY 6,Dreijenlaan 6 Scheikundegebouw 6703 HB NEDERLAND Ergo S.A. HELLAS Ergo S.A. Other 15,AG Orous Street 15123 HELLAS Humboldt-Universität zu Berlin DEUTSCHLAND Humboldt-Universität zu Berlin Education Virchow-Klinikum Experimentelle Chirurgie - Abteilung für Chirurgie und Transplantationsmedizin 1,Augustenburger Platz 13353 DEUTSCHLAND UNIVERSITE CLAUDE BERNARD LYON 1 FRANCE UNIVERSITE CLAUDE BERNARD LYON 1 Education UMR 5586 - DEPARTEMENT DE PHYSIQUE DES MATERIAUX 43,Boulevard du 11 Novembre 1918, 43 69622 FRANCE VYGON SA FRANCE VYGON SA Other TECHNICAL DEPARTMENT 5-11,Rue Adeline 5-11 95440 FRANCE Enterprise Ireland - Trading as Bioresearch Ireland ÉIRE/IRELAND Enterprise Ireland - Trading as Bioresearch Ireland Research Ceramics Research Centre Glasnevin ÉIRE/IRELAND BIOMATECH France BIOMATECH Industry Rue Pasteur 115, Z.I. L'Islon 38670 France BELLCO Italy BELLCO Industry CLINICAL AND LABORATORY RESEARCH DEPARTMENT Via Camurana 1A Italy Hide general information Medical Devices represent half of the nosocomial complications in the hospital (25 40 % of intravenous catheters are infected after 5 7 days). They are related to a relative affinity of bacteria to adhere on an artificial surface, and to develop a biofilm structure which isolate microorganisms from conventional therapies. End users and Industrials are highly concerned by morbidity and health care costs of infection. Although antibiotic bounding and silver treatment of the materials have already been proposed, their efficacy, safety and long term performances have not been established. This fundamental research program is dealing with the screening of more than 10 different surface treatment for polymers in order to design an "anti bacterial" interface. These techniques of potential interest in developping antibacterial surfaces will include: Design of specific antibacterial activity (silver, quaternary ammonium, carbon like coating + Ag, silver iodide, antiseptics). Grafting of biological molecules within the bulk or on the surface (heparin is of high potential interest). Development of non fouling surfaces concept (PEO like, PEO repelling, teflon like, suprahydrophilic, microstructurated) The activity of these materials will be screened on bacterial strains and in conditions representative of the clinical use. A fundamental approach of biofilm expression and regulation according to the different polymeric surfaces and treatments is included as an important step for the understanding of the effects. The project will be in a second time (after month 20) restricted to efficient surface treatments and to those for which the risk benefit ratio is acceptable.Polymeric changes induced by the treatment, optimization of sterilization conditions will be investigated. 5 academic partners who developped and fully control these technologies and 5 industrial partners, including 2 CRO's, will participate to this extensive project. Due to its important impact, the project is exceeding 30 % of the total cost allowed for basic research projects. However, this size expresses also the need for an EU level programme since no single partner would be able to develop it individualy. Source : cordis